Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Department of Statistics, The Research Institute of Natural Sciences, Sookmyung Women's University, Seoul, Korea.
Cancer Res Treat. 2019 Jul;51(3):1144-1155. doi: 10.4143/crt.2018.508. Epub 2018 Nov 20.
Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC.
We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients' clinico-pathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied.
The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively.
We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.
上皮性卵巢癌(EOC)精确预后模型的发现是实施个体化治疗的第一步。本研究旨在建立预测 EOC 患者治疗反应和预后的列线图。
我们全面回顾了 2007 年至 2016 年期间在两家三级医疗机构诊断和治疗 EOC 的 866 名患者的病历。收集了患者的临床病理特征、初始治疗细节、术中手术发现和生存结局。为了构建铂类药物敏感性、3 年无进展生存期(PFS)和 5 年总生存期(OS)的预测列线图,我们通过留一交叉验证测量接受者操作特征曲线(ROC)下面积(AUC)进行逐步变量选择。为了验证模型,我们应用了 10 折交叉验证。
中位观察期为 42.4 个月(四分位距,25.7 至 69.9 个月),441 名患者(50.9%)经历了疾病复发。PFS 的中位值为 32.6 个月,3 年 PFS 率为 47.8%,5 年 OS 率为 68.4%。新开发的预测铂类药物敏感性、3 年 PFS 和 5 年 OS 的列线图的 AUC 分别为 0.758、0.841 和 0.805。我们还为接受初次减瘤手术的患者开发了预测列线图。铂类药物敏感性、3 年 PFS 和 5 年 OS 的 AUC 分别为 0.713、0.839 和 0.803。
我们成功地开发了预测 EOC 患者治疗反应和预后的列线图。这些列线图有望在临床实践和临床试验设计中发挥作用。